• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大双拷贝载体具有功能性,但转导效率随载体大小的增加而下降。

Large double copy vectors are functional but show a size-dependent decline in transduction efficiency.

机构信息

Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium.

出版信息

J Biotechnol. 2010 Oct 1;150(1):37-40. doi: 10.1016/j.jbiotec.2010.07.010. Epub 2010 Jul 16.

DOI:10.1016/j.jbiotec.2010.07.010
PMID:20638430
Abstract

The development of SIN-lentivectors has paved the way for the double copy vectors (DCV), which substitute the deletion in the 3'LTR with either transgenic or insulator sequences. However, the limits of this approach remain unclear. Previous results have demonstrated that transduction efficiencies of DCV carrying large insulator inserts in their 3'LTRs were impaired in a size-dependent manner. We wondered if this was also true for promoter-transgene inserts and whether they remained functional upon integration into the genome. Therefore, we designed a series of DCV with increasing 3'LTR sizes containing different promoter-transgene combinations. Transduced cells were scored for both transduction efficiency and insert functionality. We found that the transduction efficiencies indeed were impaired in a size-dependent way. Efficiency with inserts below 1 kb linearly decreased with size, while sizes between 1 and 2 kb showed a further decrease to a minimum of 5% of an original "empty" SIN-vector. However, we did not find an LTR size that completely abolished transduction. Moreover, we demonstrated that all inserts remained functional regardless the promoter-transgene combination used. Therefore, we conclude from our data that DCV indeed remain functional, but transduction efficiencies drop radically when inserts larger than 1 kb are being used.

摘要

SIN 载体的发展为双拷贝载体 (DCV) 铺平了道路,后者用转基因或绝缘子序列替代了 3'LTR 中的缺失。然而,这种方法的局限性尚不清楚。先前的结果表明,在其 3'LTR 中携带大的绝缘子插入物的 DCV 的转导效率以大小依赖的方式受损。我们想知道这对于启动子-转基因插入物是否也成立,以及它们在整合到基因组中后是否仍然具有功能。因此,我们设计了一系列具有不同启动子-转基因组合的 3'LTR 大小增加的 DCV。转导细胞的转导效率和插入物功能都进行了评分。我们发现,转导效率确实以大小依赖的方式受损。插入物小于 1 kb 的效率呈线性下降,而大小在 1 到 2 kb 之间的效率进一步下降到原始“空”SIN 载体的 5%以下。然而,我们没有发现完全消除转导的 LTR 大小。此外,我们证明无论使用何种启动子-转基因组合,所有插入物都保持功能。因此,我们从数据中得出结论,DCV 确实仍然具有功能,但当使用大于 1 kb 的插入物时,转导效率会急剧下降。

相似文献

1
Large double copy vectors are functional but show a size-dependent decline in transduction efficiency.大双拷贝载体具有功能性,但转导效率随载体大小的增加而下降。
J Biotechnol. 2010 Oct 1;150(1):37-40. doi: 10.1016/j.jbiotec.2010.07.010. Epub 2010 Jul 16.
2
Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR.携带3'长末端重复序列(LTR)大插入片段的慢病毒载体滴度降低的机制。
Mol Ther. 2009 Sep;17(9):1527-36. doi: 10.1038/mt.2009.89. Epub 2009 Apr 21.
3
In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.通过腺病毒介导的肿瘤细胞转导原位产生假型逆转录病毒后代可增强单纯疱疹病毒胸苷激酶自杀基因疗法在体外和体内的杀伤效果。
J Gene Med. 2004 Mar;6(3):288-99. doi: 10.1002/jgm.490.
4
Modified HIV-1 based lentiviral vectors have an effect on viral transduction efficiency and gene expression in vitro and in vivo.基于HIV-1改造的慢病毒载体在体外和体内对病毒转导效率及基因表达均有影响。
Mol Ther. 2001 Sep;4(3):164-73. doi: 10.1006/mthe.2001.0450.
5
Self-inactivating lentiviral vectors with U3 and U5 modifications.具有U3和U5修饰的自失活慢病毒载体。
Virology. 1999 Aug 15;261(1):120-32. doi: 10.1006/viro.1999.9850.
6
3' self-inactivating long terminal repeat inserts for the modulation of transgene expression from lentiviral vectors.用于调节慢病毒载体转基因表达的3' 自失活长末端重复序列插入片段
Hum Gene Ther Methods. 2012 Apr;23(2):84-97. doi: 10.1089/hgtb.2011.154. Epub 2012 Mar 28.
7
Targeted transgene integration into transgenic mouse fibroblasts carrying the full-length human AAVS1 locus mediated by HSV/AAV rep(+) hybrid amplicon vector.通过单纯疱疹病毒/腺相关病毒rep(+)杂交扩增子载体介导,将靶向转基因整合到携带全长人AAVS1基因座的转基因小鼠成纤维细胞中。
Gene Ther. 2003 Sep;10(19):1691-702. doi: 10.1038/sj.gt.3302061.
8
Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters.通过含有第二代四环素反应性启动子的慢病毒载体对转基因表达进行严格控制。
J Gene Med. 2005 Jun;7(6):803-17. doi: 10.1002/jgm.712.
9
Multiply attenuated, self-inactivating lentiviral vectors efficiently deliver and express genes for extended periods of time in adult rat cardiomyocytes in vivo.多重减毒、自我失活的慢病毒载体可在成年大鼠心肌细胞体内长时间有效地递送并表达基因。
Circulation. 2003 May 13;107(18):2375-82. doi: 10.1161/01.CIR.0000065598.46411.EF. Epub 2003 Apr 14.
10
Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors.用修饰的三质粒慢病毒载体转导后,脐血CD34(+)来源的造血细胞(包括发育中的T细胞和NOD/SCID小鼠再植细胞)中的转基因表达增强。
Mol Ther. 2001 Apr;3(4):438-48. doi: 10.1006/mthe.2001.0282.

引用本文的文献

1
Nanobodies and their derivatives: pioneering the future of cancer immunotherapy.纳米抗体及其衍生物:引领癌症免疫治疗的未来。
Cell Commun Signal. 2025 Jun 5;23(1):271. doi: 10.1186/s12964-025-02270-4.
2
Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies.双靶点嵌合抗原受体T细胞疗法在临床前和临床研究中的进展与未来方向
J Immunol Res. 2025 Jan 15;2025:5845167. doi: 10.1155/jimr/5845167. eCollection 2025.
3
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
CD19/CD20 双靶点嵌合抗原受体工程化自然杀伤细胞对急性淋巴细胞白血病显示出增强的细胞毒性。
J Transl Med. 2024 Mar 13;22(1):274. doi: 10.1186/s12967-024-04990-6.
4
Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy.通过定向进化工程化一种程序性死亡配体 1 靶向单域抗体用于 SynNotch 门控细胞治疗。
ACS Nano. 2024 Mar 19;18(11):8531-8545. doi: 10.1021/acsnano.4c01597. Epub 2024 Mar 8.
5
Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update.双特异性 T 细胞衔接器和嵌合抗原受体 T 细胞疗法在胶质母细胞瘤中的应用:最新进展。
Curr Oncol. 2023 Sep 15;30(9):8501-8549. doi: 10.3390/curroncol30090619.
6
T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.经新型 VHH 基嵌合抗原受体修饰的 T 细胞对 CD19 表现出与 FMC63 基嵌合抗原受体相当的肿瘤杀伤效力。
Front Immunol. 2023 Feb 16;14:1063838. doi: 10.3389/fimmu.2023.1063838. eCollection 2023.
7
Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment.CARs 疗法的现代进展与未来治疗新方法的探索
Int J Mol Sci. 2022 Nov 30;23(23):15006. doi: 10.3390/ijms232315006.
8
Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR.理性蛋白设计产生的 CD20 CAR 比 CD19 CAR 具有更好的抗肿瘤疗效。
Cancer Immunol Res. 2023 Feb 3;11(2):150-163. doi: 10.1158/2326-6066.CIR-22-0504.
9
Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies.双靶点嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤的现状与展望
Cancers (Basel). 2022 Jun 30;14(13):3230. doi: 10.3390/cancers14133230.
10
Nanobody-based CAR-T cells for cancer immunotherapy.用于癌症免疫治疗的基于纳米抗体的嵌合抗原受体T细胞。
Biomark Res. 2022 Apr 25;10(1):24. doi: 10.1186/s40364-022-00371-7.